AKT Kinase Inhibitor is a potent inhibitor of Akt kinase with antitumor activity. Akt is a serine-threonine protein kinase critical for cell survival, proliferation, growth, membrane recruitment, and phosphorylation processes, whose dysregulation is associated with various cancers and rare diseases[1, 2]. AKT Kinase Inhibitor is commonly used in research focusing on cell proliferation inhibition, apoptosis induction, and diseases related to Akt dysregulation[3, 4, 5].
References:
[1] PERVANIDIS K A, D’ANGELO G D, WEISNER J, et al. Akt inhibitor advancements: from capivasertib approval to covalent-allosteric promises[J]. Journal of medicinal chemistry, 2024, 67(8): 6052-6063.
[2] RHODES N, HEERDING D A, DUCKETT D R, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity[J]. Cancer research, 2008, 68(7): 2366-2374.
[3] PAL S K, RECKAMP K, YU H, et al. Akt inhibitors in clinical development for the treatment of cancer[J]. Expert opinion on investigational drugs, 2010, 19(11): 1355-1366.
[4] UKO N E, GÜNER O F, MATESIC D F, et al. Akt pathway inhibitors[J]. Current topics in medicinal chemistry, 2020, 20(10): 883-900.
[5] LINDSLEY C W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update[J]. Current topics in medicinal chemistry, 2010, 10(4): 458-477.
AKT Kinase Inhibitor是一种具有抗肿瘤活性的Akt激酶抑制剂。Akt是一种丝氨酸-苏氨酸蛋白激酶，在细胞存亡、增殖生长、细胞膜招募与磷酸化过程中起关键作用，其信号异常与多种癌症及罕见病相关[1,2]。AKT Kinase Inhibitor通常用于细胞增殖抑制、凋亡诱导和Akt失调相关疾病的研究[3,4,5]。